REG - Destiny Pharma PLC - Director/PDMR Shareholding

Destiny PharmaAnnouncement

26/04/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220426:nRSZ4156Ja&default-theme=true

RNS Number : 4156J  Destiny Pharma PLC  26 April 2022

 

 

 

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Notification of Transactions by Persons Discharging Managerial
Responsibilities (PDMRs)/Persons Closely Associated (PCAs)

 

Brighton, United Kingdom - 26 April 2022 - Destiny Pharma plc (AIM: DEST) a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
it was notified on 26 April 2022 that on that same day, Dr William Love, Chief
Scientific Officer of the Company, transferred 580,000 ordinary shares of 1
pence in the Company ("Ordinary Shares") to his wife, a PCA, by way of gift
for nil consideration.

Following the transfer, Dr William Love's beneficial interest in the Company
remains unchanged at 6,509,500 Ordinary Shares, representing 8.88 per cent. of
the total issued share capital.

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications

Mary Clark / Manel Mateus / Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and XF-73 nasal gel, which has
recently completed a positive Phase 2b clinical trial targeting the prevention
of post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of
COVID-19 and other viral respiratory infections and has earlier grant funded
XF research projects.

 

For further information, please visit  www.destinypharma.com
(http://www.destinypharma.com)

 

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under Article 17 of
MAR.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Dr William Love
 2.                        Reason for the Notification
 a)                        Position/status                                              Chief Scientific Officer
 b)                        Initial notification/Amendment                               Initial Notification
 3.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Destiny Pharma plc
 b)                        LEI                                                          213800O9WH9Z38EHAC95
 4.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument  Ordinary shares of 1p each ("Ordinary Shares")
                           Identification code                                          DEST      GB00BDHSP575
 b)                        Nature of the transaction                                    Transfer of Ordinary Shares, by way of gift, to Carol Love, a Person Closely
                                                                                        Associated with him, for nil consideration.
 c)                        Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                                        0(gift)  580,000
 d)                        Aggregated information:

                           ·      Aggregated volume                                     See 4c) above

                           ·      Price
 e)                        Date of the transaction                                      26 April 2022
 f)                        Place of the transaction                                     Off-Market

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See 4c) above

e)

Date of the transaction

26 April 2022

f)

Place of the transaction

Off-Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFFSSFIRFIF